Immunobiology of Cancer

NCT00767533 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 84

Last updated 2016-07-22

No results posted yet for this study

Summary

To learn whether or not an Interferon defect in cell signaling, recently discovered in immune cells from melanoma patients as well as breast cancer patients, is common to all cancers.

Conditions

  • Neoplasms

Sponsors & Collaborators

Principal Investigators

  • Peter P Lee · Stanford University

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-10-31
Primary Completion
2011-10-31
Completion
2011-10-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00767533 on ClinicalTrials.gov